ATE431745T1 - Ltb4 als adjuvans für impfstoffe - Google Patents

Ltb4 als adjuvans für impfstoffe

Info

Publication number: ATE431745T1
Authority: AT; Austria
Prior art keywords: adjuvant; ltb4; vaccines; vaccine; enhancing
Prior art date: 2001-07-05

Application number

AT02737698T

Other languages

English (en)

Inventor

Louis Flamand

Jean Gosselin

Pierre Borgeat

Original Assignee

Ltb4 Sweden Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-05

Filing date

2002-06-26

Publication date

2009-06-15

2002-06-26 Application filed by Ltb4 Sweden Ab filed Critical Ltb4 Sweden Ab

2009-06-15 Application granted granted Critical

2009-06-15 Publication of ATE431745T1 publication Critical patent/ATE431745T1/de

Links

229960005486 vaccine Drugs 0.000 title abstract 3
VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 title abstract 2
239000002671 adjuvant Substances 0.000 title 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
239000012646 vaccine adjuvant Substances 0.000 abstract 1
229940124931 vaccine adjuvant Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Mycology (AREA)
Microbiology (AREA)
Pulmonology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Refinement Of Pig-Iron, Manufacture Of Cast Iron, And Steel Manufacture Other Than In Revolving Furnaces (AREA)
Vending Machines For Individual Products (AREA)
Amplifiers (AREA)

AT02737698T 2001-07-05 2002-06-26 Ltb4 als adjuvans für impfstoffe ATE431745T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30270501P	2001-07-05	2001-07-05
PCT/CA2002/000955 WO2003004054A1 (en)	2001-07-05	2002-06-26	Ltb4 as vaccine aduvant

Publications (1)

Publication Number	Publication Date
ATE431745T1 true ATE431745T1 (de)	2009-06-15

Family

ID=23168877

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02737698T ATE431745T1 (de)	2001-07-05	2002-06-26	Ltb4 als adjuvans für impfstoffe

Country Status (8)

Country	Link
US (1)	US7914800B2 (de)
EP (1)	EP1401492B1 (de)
AT (1)	ATE431745T1 (de)
CA (1)	CA2452008C (de)
DE (1)	DE60232413D1 (de)
DK (1)	DK1401492T3 (de)
ES (1)	ES2329118T3 (de)
WO (1)	WO2003004054A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7473708B2 (en)	1996-02-15	2009-01-06	Jean Gosselin	Agents with leukotriene B4-like antiviral (enveloped RNA) activities
WO2005102309A2 (en) *	2004-04-26	2005-11-03	Ltb4 Sweden Ab	In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
ATE474603T1 (de) *	2004-09-20	2010-08-15	Ltb4 Sweden Ab	Stabilisiertes leukotrien b4 (ltb4) pharmazeutikum
CA2803444A1 (en) *	2010-06-29	2012-01-05	Universite Laval	Use of leukotriene b4 in combination with a toll-like receptor ligand, a rig-l-like receptor ligand or a nod-like receptor ligand to enhance the innate immune response

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5789441A (en) *	1996-02-15	1998-08-04	Virocell Inc.	Leukotriene B4 as an antiviral and anti-neoplastic agent
US5919480A (en) *	1996-06-24	1999-07-06	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Liposomal influenza vaccine composition and method

2002
- 2002-06-26 WO PCT/CA2002/000955 patent/WO2003004054A1/en not_active Ceased
- 2002-06-26 DK DK02737698T patent/DK1401492T3/da active
- 2002-06-26 ES ES02737698T patent/ES2329118T3/es not_active Expired - Lifetime
- 2002-06-26 US US10/482,393 patent/US7914800B2/en not_active Expired - Fee Related
- 2002-06-26 CA CA2452008A patent/CA2452008C/en not_active Expired - Fee Related
- 2002-06-26 DE DE60232413T patent/DE60232413D1/de not_active Expired - Lifetime
- 2002-06-26 AT AT02737698T patent/ATE431745T1/de not_active IP Right Cessation
- 2002-06-26 EP EP02737698A patent/EP1401492B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2452008C (en)	2012-03-06
EP1401492A1 (de)	2004-03-31
US20040208882A1 (en)	2004-10-21
WO2003004054A1 (en)	2003-01-16
US7914800B2 (en)	2011-03-29
EP1401492B1 (de)	2009-05-20
ES2329118T3 (es)	2009-11-23
DK1401492T3 (da)	2009-09-14
CA2452008A1 (en)	2003-01-16
DE60232413D1 (en)	2009-07-02

Legal Events

Date	Code	Title	Description
2009-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
WO2006068663A3 (en)	2006-11-16	Vaccine compositions for treating coronavirus infection
DK1113816T3 (da)	2006-04-03	Influenzavirus-vaccinesammensætning
IS4518A (is)	1999-01-10	Nýtt lyfjaform fyrir bóluefni
PT1187629E (pt)	2005-02-28	Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
ATE426412T1 (de)	2009-04-15	Adjuvante influenza-vakzine
ATE397942T1 (de)	2008-07-15	Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen
ATE499113T1 (de)	2011-03-15	Influenzavirus-impfstoffzusammensetzung
MA29406B1 (fr)	2008-04-01	Vaccin toxoide alpha de c. perfringens
EP1504112A4 (de)	2006-02-08	Entwicklung einer vakzine zur prävention von infektionen mit dem filovirus bei primaten
NO20013749D0 (no)	2001-07-31	Immunologisk adjuvansforbindelse
GB2386072A (en)	2003-09-10	Novel vaccine
WO2006031795A8 (en)	2007-07-12	Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
DK1259259T3 (da)	2011-08-01	Mucosal adjuvansformulering
ATE521621T1 (de)	2011-09-15	Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans
ATE458496T1 (de)	2010-03-15	Hiv-vakzine und anwendungsverfahren
WO2003039592A3 (de)	2003-10-23	Zelluläre impfstoffe mit adjuvanzien
EP1395283A4 (de)	2005-06-08	Heterologer schutz, induziert durch immunisierung mit der invaplex-vakzine
DK1401492T3 (da)	2009-09-14	LTB4 som vaccineadjuvans
BRPI0414073A (pt)	2006-10-24	método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
ATE471990T1 (de)	2010-07-15	Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
WO2004097000A3 (en)	2007-10-04	Ligand-exchange functional antigens, and use of same in pharmaceutical vaccine compositions
WO2005123112A3 (en)	2006-04-27	Method of enhancing the immune response to a vaccine
GB2444676A (en)	2008-06-11	Adjuvanted vaccine
WO2002032455A3 (en)	2003-09-18	Vaccine
WO2004083390A3 (en)	2006-06-15	Virulent systemic feline calicivirus